Clinical trial

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

NCT04252365

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2020-03-01

PhasePHASE2

Study timeline

Study start (estimated)2020-03-01Date precision: day

Registry last updated2020-02-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Nsclcunresolved

Interventions

SintilimabDRUG

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Guangdong Association of Clinical Trialslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04252365 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.